MGAT5 and neoplasm: To determine the effects of Mgat5 loss on tumor clearance in an immunosuppressive microenvironment, we used CRISPR to KO Mgat5 in 2 non–T cell–inflamed (“cold”) clonal cell lines (6694c2 and 6419c5), which reflect the myeloid-rich TME of most PDAC tumors.